Claims

1.	A combination composition which comprises: (a) propionyl Lcarnitine or a pharmacologically acceptable salt thereof ; and (b) an inositol phosphate.

2.	The composition of claim 1, wherein the inositol phosphate is selected from the group consisting of inositol monophosphate, inositol tetraphosphate, inositol pentaphosphate and inositol hexaphosphate (IP6).

3.	The composition of claim 1 or 2, wherein the ingredient (a) further comprises a"carnitine"selected from the group comprising Lcarnitine, acetyl Lcarnitine, butyryl Lcarnitine, valeryl Lcarnitine, isovaleryl Lcarnitine or their pharmacologically acceptable salts or mixtures thereo£.

4.	The composition of claims 13, wherein ingredient (b) further comprises inositol.

5.	The composition of claims 14, wherein the weight ratio (a): (b) is from 1: 10 to 1: 1.

6.	The composition of any of the preceding claims, wherein the ingredient (b) occurs as a vegetable product or extract of vegetable products containing same.

7.	The composition of claims 6, wherein the vegetal product is bran or brown rice and/or their extracts.

8.

The composition of any of the preceding claims, wherein the pharmacologically acceptable salt of Lcarnitine or alkanoyl Lcarnitine is selected from the group comprising: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; orotate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.

9.	The composition of any of the preceding claims, which further comprises vitamins, coenzymes, mineral substances and antioxidants.

10.	The composition of any of the preceding claims, orally administrable, in the form of a dietary supplement.

11.	The composition of any of the preceding claims 19, orally, parenterally, rectally or transdermally administrable in the form of a medicament.

12.	The dietary supplement of claim 10, for the prevention of tissue anoxic forms, cardiac or nervous disturbances, muscular energy deficits, asthenia and fatigue, inflammatorytype abnormalities, and tissue proliferation forms.

13.

The medicament of claim 11 for the therapeutic treatment of free radical inducedpathologies, for the treatment of cardiovascular or cerebral disorders due to tissue anoxia or ageing, alterations of blood coagulation such as thrombosis, inflammatorytype abnormalities, muscular energy deficits accompanied by asthenia and fatigue and as adjuvant in the treatment of tissue proliferation forms.

14.	The dietary supplement of claim 12, in the form of tablets, pills, capsules, granulates or syrups.

15.	The medicament of claim 13, in the form of tablets, pills, capsules, granulates, syrups, suppositories, vials or drops.

16.

Use of a combination composition which comprises as character izing active ingredients: (a) propionyl Lcarnitine or a pharmacologically acceptable salt thereof; (b) an inositol phosphate selected from the group consisting of inositol monophosphate, inositol tetraphosphate, inositol penta phosphate and inositol hexaphosphate (IP6) for preparing a dietary supplement or medicament useful for the prevention and/or treatment of cardiovascular or neurocerebral disorders due to chronic or acute tissue anoxia, energy deficits, inflammatorytype abnormalities, nervous and muscular astheniae and of tissue proliferation forms.

17.

The use of claim 16, wherein the ingredient (a) further comprises a"carnitine"selected from the group comprising Lcarnitine, acetyl Lcarnitine, butyryl Lcarnitine, valeryl Lcarnitine, isovaleryl L carnitine or their pharmacologically acceptable salts or mixtures thereof and the ingredient (b) further comprising inositol.